Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy

AIDS

Volumn 29, Issue 17, 2015, Pages 2353-2359

  Pyra, Maria ^a,b   Heffron, Renee ^a,b   Mugo, Nelly R ^b,c,d   Nanda, Kavita ^e   Thomas, Katherine K ^a   Celum, Connie ^a,b   Kourtis, Athena P ^f   Were, Edwin ^g,j   Rees, Helen ^h,p   Bukusi, Elizabeth ^d,n   Baeten, Jared M ^a,b   Wald, Anna ^a   Lingappa, Jairam ^a   Campbell, Mary ^a   Corey, Lawrence ^a   Hughes, James P ^a   Magaret, Amalia ^a   Morrow, Rhoda ^a   Mullins, James I ^a   Coetzee, David ⁱ   Fife, Kenneth ^j   Essex, Max ^k   Makhema, Joseph ^k   Katabira, Elly ^b,l   Ronald, Allan ^l   Allen, Susan ^m   Kayitenkore, Kayitesi ^m   Karita, Etienne ^m   Cohen, Craig ⁿ   Kanweka, William ^m   Vwalika, Bellington ^m   Kapiga, Saidi ^o   Manongi, Rachel ^o   Farquhar, Carey ^b   Kiarie, James ^b   Inambao, Mubiana ^m   Delany Moretlwe, Sinead ^p   De Bruyn, Guy ^p   Gray, Glenda ^p   McIntyre, James ^p   Mugo, Nelly Rwamba ^b   Donnell, Deborah ^b   Coombs, Robert W ^b   Lingappa, Jairam R ^b   McElrath, M Juliana ^b   Fife, Kenneth H ^j   Tumwesigye, Elioda ^q   Ndase, Patrick ^b   Cohen, Craig R ⁿ   Wangisi, Jonathan ^r   Campbell, James D ^r   Tappero, Jordan W ^r   more..

^a Department of Epidemiology ^*

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e FAMILY HEALTH INTERNATIONAL   (United States)

^f NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^g MOI UNIVERSITY   (Kenya)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

^j INDIANA UNIVERSITY   (United States)

^k BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^l MAKERERE UNIVERSITY   (Uganda)

^m EMORY UNIVERSITY   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o HARVARD UNIVERSITY   (United States)

^p UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^q Kabwohe Clinical Research Center   (Uganda)

^r CDC Uganda   (Uganda)

more..

Author keywords

antiretroviral agents; hormonal contraception; women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; INJECTABLE CONTRACEPTIVE AGENT; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT; CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AFRICA; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MIDDLE AGED; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOUTHERN AFRICAN; VIRUS LOAD; CONTRACEPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; LONGITUDINAL STUDY; MALE; PREGNANCY; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954559645     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000827     Document Type: Article

References (28)

1. Cleland J, Machiyama K. Unmet need for family planning: past achievements and remaining challenges. Semin Reprod Med 2015; 33:11-16.
2. Thurman AR, Anderson S. Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics. Am J Reprod Immunol 2014; 71:523-530.
3. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Healthcare 2008; 13:123-132.
4. Celum C,Wald A, Lingappa JR,Magaret AS,Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439.
5. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
6. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Hormonal contraceptive use and risk of HIV-1 transmission: A prospective cohort analysis. Lancet Infect Dis 2012; 12:19-26.
7. Andersen PK, Gill RD. Cox's regression model for counting processes: A large sample study. Ann Stat 1982; 10:1100-1120.
8. Cohn SE, Park J-G, Watts DH, Stek A, Hitti J, Clax PA, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2006; 81:222-227.
9. Schwartz SR, Rees H, Mehta S, Venter WDF, Taha TE, Black V. High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLoS One 2012; 7:e36039.
10. Watts DH, Park J-G, Cohn SE, Yu S, Hitti J, Stek A, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008; 77:84-90.
11. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002; 29:471-477.
12. Stuart GS, Moses A, Corbett A, Phiri G, Kumwenda W, Mkandawire N, et al. Pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr 2011; 58:e40-e43.
13. Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kerr S, Ahluwalia J, et al. Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. J Acquir Immune Defic Syndr 2014; 66:e50-e52.
14. Nanda K, Delany-Moretlwe S, Dube K, Lendvay A, Kwok C, Molife L, et al. Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. AIDS 2013; 27 (Suppl 1):S17-S25.
15. Perry SH, Swamy P, Preidis GA, Mwanyumba A, Motsa N, Sarero HN. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS Lond Engl 2014; 28:791-793.
16. Nanda K, Amaral E, Hays M, Viscola MAM, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008; 90:965-971.
17. Scarsi K, Darin K, Nakalema S, Back D, Byakika-Kibwika P, Else L, et al. Levonorgestrel implantREFV-based ART: unintended pregnancies and associated PK data. CROI 25 February 2015, Seattle, WA: CROI; 2015.
18. Scarsi K, Lamorde M, Darin K, Dilly Penchala S, Else L, Nakalema S, et al. Efavirenz-but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc 2014; 17 (4 Suppl 3):19484.
19. Vieira CS, Bahamondes MV, de Souza RM, Brito MB, Rocha Prandini TR, Amaral E, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrelreleasing implant pharmacokinetics in HIV-positive women. J Acquir Immune Defic Syndr 2014; 66:378-385.
20. McCarty EJ, Keane H, Quinn K, Quah S. Implanon: failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. Int J STD AIDS 2011; 22:413-414.
21. Leticee N, Viard J-P, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2012; 85:425-427.
22. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon( in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Healthcare 2007; 33:277-278.
23. Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kriengsinyot R, Ahluwalia J, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. JAIDS J Acquir Immune Defic Syndr 2013; 62:534-539.
24. Sevinsky H, Eley T, Persson A, Garner D, Yones C, Nettles R, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther 2011; 16:149-156.
25. Pillay Y. SA-ChangeImplanon.pdf. 2014. http://sahivsoc.org/ upload/documents/Circular%20-%20Changes%20in%20the% 20Prescription%20of%20Progestin%20Subdermal%20Im plants.pdf?utm-source=GraphicMail&utm-medium=E-Mail &utm-term=NewsletterLink&utm-campaign=Newsletter&utm-content=. [Accessed 5 November 2014].
26. Patel R, Onono M, Gandhi M, Hagey J, Blat C, Shade S, et al. Pregnancy rates among HIV-positive women using various forms of antiretroviral therapy and contraceptives in Kenya. 5th International Workshop on HIV & Women. Seattle, WA: 21-22 February 2015.
27. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, Abrams EJ. Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in sub-Saharan Africa: A cohort study. PLoS Med 2010; 7:e1000229.
28. Tweya H, Feldacker C, Breeze E, Jahn A, Haddad LB, Ben-Smith A, et al. Incidence of pregnancy among women accessing antiretroviral therapy in urban Malawi: A retrospective cohort study. AIDS Behav 2013; 17:471-478.